Roche, Chiasma partner to develop, commercialise Octreolin

Roche and Chiasma have partnered to develop and commercialise Octreolin, an investigational oral regimen for acromegaly and neuroendocrine tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Source: Endocrine - Category: Endocrinology Source Type: research
ConclusionsIn the real-life scenario ~54% of patients with acromegaly resistant to first-generation SSA, may normalize IGF-1 with pasireotide; however, 63% experienced glucose control deterioration.
Source: Endocrine - Category: Endocrinology Source Type: research
ConclusionSleep apnea is common among patients with acromegaly, and is often diagnosed prior to their acromegaly diagnosis. These results support early screening for sleep apnea in patients with acromegaly and awareness for acromegaly in patients with sleep apnea.
Source: Endocrine - Category: Endocrinology Source Type: research
CONCLUSIONS: We will focus on the issues regarding the measurement and interpretation of IGF-I concentrations in the management of acromegaly patients. PMID: 30311754 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
Authors: Yuen KC, Popovic V Abstract Previous studies have implicated the growth hormone (GH)/IGF-I axis as an important mediator of cancer risk in humans and animals. Evidence supporting this notion is derived from animal studies, epidemiological observations, patients with acromegaly and from therapeutic manipulation of GH and IGF-I actions. Therefore, the use of GH therapy in patients with a history of malignancy raises hypothetical safety concerns. Reassuringly, GH therapy in childhood cancer survivors has not been confirmed to increase the cancer risk. Conversely, the risk of occurrence of a second neoplasm ma...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Claessen KM, Pereira AM, Biermasz NR Abstract Acromegaly patients suffer from pathologically high growth hormone (GH) and IGF-1 levels that in 99% of cases is due to a GH-producing pituitary adenoma. During active disease, GH excess is associated with a number of pathological conditions, such as hypertension, hypertrophic cardiomyopathy, sleep apnea, arthropathy, vertebral fractures and insulin resistance. After adequate treatment in the form of transsphenoidal surgery, radiotherapy, medical treatment or by a combination of these treatment modalities, several comorbid conditions improve considerably. Howev...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Publication date: Available online 12 October 2018Source: Academic RadiologyAuthor(s): Zongming Wang, Zhigang Mao, Xiangsong Zhang, Dongsheng He, Xin Wang, Qiu Du, Zheng Xiao, Diming Zhu, Yonghong Zhu, Haijun WangRationale and ObjectivesIt is clinically essential, but sometimes challenging, to distinguish pituitary tissue from pituitary adenomas (PAs). It is helpful to avoid damage of pituitary tissue during management. We evaluated the ability of 13N-ammonia positron emission tomography (PET)/computed tomography (CT) to locate and distinguish pituitary tissue from PAs.Materials and MethodsForty-eight patients (four with p...
Source: Academic Radiology - Category: Radiology Source Type: research
Authors: Bolanowski M, Jawiarczyk-Przybyłowska A, Halupczok-Żyła J Abstract Osteoporosis is a systemic disease characterized by bone mass and density loss leading to fragility fractures. Osteoporosis due to endocrine disorders is an example of secondary osteoporosis. The harmful effects on bones are common in patients harboring pituitary tumors (acromegaly, prolactinoma, Cushing's disease) and suffering from hypopituitarism. Increased fracture risk and high healthcare costs of fractured patients are their consequences. The coexistence of some of these disorders and hypogonadism results in severe osteoporosis. Th...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
It has been reported that the single nucleotide polymorphism (SNP) rs2854744 at the − 202 locus of insulin-like growth factor binding protein-3 (IGFBP3) is associated with serum levels and a number of malignan...
Source: BMC Medical Genetics - Category: Genetics & Stem Cells Authors: Tags: Research article Source Type: research
Clinical Endocrinology,Volume 0, Issue ja, -Not available-.
Source: Clinical Endocrinology - Category: Endocrinology Authors: Source Type: research
More News: Acromegaly | Neurology | Pharmaceuticals